2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113259
    7α-Hydroxy-4-cholesten-3-one 3862-25-7 99.60%
    7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1.
    7α-Hydroxy-4-cholesten-3-one
  • HY-113426
    Nepsilon-Acetyl-L-lysine 692-04-6 ≥98.0%
    Nepsilon-Acetyl-L-lysine, an endogenous metabolite, is an R-chain N-acetylated α amino acid.
    Nepsilon-Acetyl-L-lysine
  • HY-117656
    ESI-05 5184-64-5 99.78%
    ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC50 of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders.
    ESI-05
  • HY-133685
    N-Hexanoyl-L-homoserine lactone 147852-83-3
    N-Hexanoyl-L-homoserine lactone is a short-chained N-acyl homoserine lactone (AHL). N-hexanoyl-L-homoserine lactone is also a mediator of bacterial quorum-sensing regulation. N-hexanoyl-L-homoserine lactone promotes lipid accumulation in algae. AHL is an intercellular communication signal molecule in the quorum sensing system of Gram-negative bacteria and a medium for mediating information exchange between eukaryotic plants and prokaryotic bacteria. AHL can affect bacteria activities, such as biofilm formation, pigment synthesis, and antibiotic synthesis.
    N-Hexanoyl-L-homoserine lactone
  • HY-136561
    GRK5-IN-2 1642839-27-7 99.92%
    GRK5-IN-2 (compound 707), a pyridine-based bicyclic compound, is a potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor with an IC50 of 49.7 μM. GRK5-IN-2 regulates the expression and/or release of insulin and is useful for the metabolic disease research.
    GRK5-IN-2
  • HY-152947
    ELOVL6-IN-4 1170321-92-2 98.63%
    ELOVL6-IN-4 is a potent, selective, and orally active long chain fatty acid elongase 6 (ELOVL6) inhibitor with IC50s of 79 nM and 94 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-4 shows excellent selectivity over the other human ELOVL subtypes (ELOVL1, -2, -3, and -5) and mouse ELOVL3.
    ELOVL6-IN-4
  • HY-P10000
    Peptide YY (PYY) (3-36), Human 123583-37-9 98.57%
    Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion.
    Peptide YY (PYY) (3-36), Human
  • HY-W001083
    3-Hydroxyphenylacetic acid 621-37-4 ≥99.0%
    3-Hydroxyphenylacetic acid is an orally active flavonoid metabolite produced by intestinal flora, with blood pressure-lowering activity. 3-Hydroxyphenylacetic acid can also inhibit ferroptosis by upregulating the expression of GPX4, thereby improving spermatogenic dysfunction in aged mice. In addition, abnormal levels of 3-Hydroxyphenylacetic acid are closely related to certain diseases, such as autism spectrum disorders.
    3-Hydroxyphenylacetic acid
  • HY-W016715
    L-Cysteine hydrochloride hydrate 7048-04-6 ≥98.0%
    L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and insulin and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes.
    L-Cysteine hydrochloride hydrate
  • HY-W019883
    Dipotassium hydrogen phosphate 7758-11-4 ≥99.0%
    Dipotassium hydrogen phosphate is a salt. Dipotassium hydrogen phosphate can enhance the lipase production of Rhizopous oligosporous in neutral pH phosphate buffer. Dipotassium hydrogen phosphate can be used as a pharmaceutical excipient, such as a pH adjuster, a buffer.
    Dipotassium hydrogen phosphate
  • HY-113147
    L-Palmitoylcarnitine 2364-67-2 ≥98.0%
    L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2.
    L-Palmitoylcarnitine
  • HY-17566
    Capreomycin sulfate 1405-37-4 ≥99.0%
    Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease.
    Capreomycin sulfate
  • HY-18282
    AZ876 898800-26-5 99.77%
    AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis.
    AZ876
  • HY-13646
    Encequidar 849675-66-7 ≥98.0%
    Encequidar (HM30181; HM30181A) is a potent and selective inhibitor of P-glycoprotein.
    Encequidar
  • HY-128895
    KL1333 1800405-30-4 ≥98.0%
    KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures.
    KL1333
  • HY-B0254
    Glipizide 29094-61-9 99.83%
    Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans.
    Glipizide
  • HY-B0422
    Nateglinide 105816-04-4 99.95%
    Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.
    Nateglinide
  • HY-B0782A
    Acetazolamide sodium 1424-27-7 99.54%
    Acetazolamide sodium is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.
    Acetazolamide sodium
  • HY-137978A
    Ezurpimtrostat hydrochloride 1914148-73-4 99.29%
    Ezurpimtrostat hydrochloride (compound 2-3) is a potent and orally active anti-fibrotic agent. Ezurpimtrostat hydrochloride reduces significantly the liver fibrosis in DEN (diethyl nitrosamine) cirrhotic rat model. Ezurpimtrostat hydrochloride can be used for the research of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases .
    Ezurpimtrostat hydrochloride
  • HY-14229
    TGR5 Receptor Agonist 1197300-24-5 99.71%
    TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC50s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca2+ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity.
    TGR5 Receptor Agonist
Cat. No. Product Name / Synonyms Application Reactivity